Abstract: The invention is a multi-purpose system and methods that focuses on the prevention of congestive heart failure (CHF) exacerbations by identifying the population at risk, examining their use of medications that optimize ventricular function, tracking weight changes through different phases of illness, and retrieving vital sign and laboratory data needed for treatment intensification.

Abstract: System and methods for collecting, sharing and analyzing data of Electronic Medical Records (EMRs) for improved health analytics. Quality of health care delivery is assessed and improved through use of data from EMRs. For example, data may be analyzed for a variety of purposes, including to determine variation in performance of a practice site, a group practice, or an individual clinician for the patient population on a given treatment or to identify a risk of disease for patients of the patient population.

Abstract: A system and method for estimating HbA1c, diabetic patient treatment response and hypoglycemia risk using data obtained from patient self-monitoring of blood glucose. The system includes a computer having a processor, data storage, display, and data input ports. The data storage stores an insulin manager module that has instructions performed by the processor when self-monitoring of blood glucose (SMBD) data is provided to the computer via one of the data input ports. The processor uses the SMBD data to generate reports displaying estimated HbAIc and other factors effecting blood glucose levels in a diabetic patient and prescribes insulin treatment plans.

Abstract: The invention provides methods for optimizing therapeutic efficacy for treating hypercholesterolemia in a subject having a cardiovascular disease (CVD), comprising (a) determining subject characteristics that affect the likelihood of reaching a goal level of low density lipoprotein (LDL); and (b) obtaining success probabilities of a variety of statin treatments for reaching said goal level of LDL using said subject characteristics and a multivariate model; and (c) administrating the optimal statin treatment with the highest success probability of step (b) to said subject thereby optimizing therapeutic efficacy for treating hypercholesterolemia in said subject.